Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Binge Eating Disorder Associated With Obesity
View Full LandscapeTarget Indication
Binge Eating Disorder Associated With Obesity
Clinical Trial
NCT00221442Last updated: 8/20/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Zonegran
Zonegran is indicated as: monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
View on EMA